AR066956A1 - Derivados de [1,10]-fenantrolina, composiciones farmaceuticas que los contienen, metodo de preparacion y uso para el tratamiento de enfermedades neurodegenerativas o hematologicas. - Google Patents

Derivados de [1,10]-fenantrolina, composiciones farmaceuticas que los contienen, metodo de preparacion y uso para el tratamiento de enfermedades neurodegenerativas o hematologicas.

Info

Publication number
AR066956A1
AR066956A1 ARP080102479A ARP080102479A AR066956A1 AR 066956 A1 AR066956 A1 AR 066956A1 AR P080102479 A ARP080102479 A AR P080102479A AR P080102479 A ARP080102479 A AR P080102479A AR 066956 A1 AR066956 A1 AR 066956A1
Authority
AR
Argentina
Prior art keywords
fenantroline
neurodegenerative
derivatives
preparation
treatment
Prior art date
Application number
ARP080102479A
Other languages
English (en)
Spanish (es)
Inventor
Gil Ana Martinez
Morera Ana Castro
Arrieta Laura Rubio
Jorge Sanchez-Quesada
Egea Paola Usan
Padilla Miguel Medina
Palomero Esther Garcia
Cascon Mercedes Alonso
Original Assignee
Neuropharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropharma Sa filed Critical Neuropharma Sa
Publication of AR066956A1 publication Critical patent/AR066956A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP080102479A 2007-06-11 2008-06-11 Derivados de [1,10]-fenantrolina, composiciones farmaceuticas que los contienen, metodo de preparacion y uso para el tratamiento de enfermedades neurodegenerativas o hematologicas. AR066956A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07380167A EP2002863A1 (en) 2007-06-11 2007-06-11 [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases

Publications (1)

Publication Number Publication Date
AR066956A1 true AR066956A1 (es) 2009-09-23

Family

ID=38596362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102479A AR066956A1 (es) 2007-06-11 2008-06-11 Derivados de [1,10]-fenantrolina, composiciones farmaceuticas que los contienen, metodo de preparacion y uso para el tratamiento de enfermedades neurodegenerativas o hematologicas.

Country Status (13)

Country Link
US (2) US8592446B2 (enExample)
EP (2) EP2002863A1 (enExample)
JP (1) JP2010529167A (enExample)
CN (1) CN101801461A (enExample)
AR (1) AR066956A1 (enExample)
AU (1) AU2008263897A1 (enExample)
CA (1) CA2690455A1 (enExample)
CL (1) CL2008001719A1 (enExample)
MX (1) MX2009013482A (enExample)
RU (1) RU2009148821A (enExample)
TW (1) TW200914016A (enExample)
UY (1) UY31143A1 (enExample)
WO (1) WO2008152068A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6000272B2 (ja) 2010-12-01 2016-09-28 中国石油化工股▲ふん▼有限公司 窒素のオルソ位にアシル基が置換した窒素含有複素環式化合物およびそのアミナール鉄(ii)錯体の製造方法
CN102532201B (zh) * 2010-12-01 2014-11-05 中国石油化工股份有限公司 甲酰基取代的1,10-菲咯啉配合物的制备及由此制备的配合物作为催化剂的应用
CN102558241B (zh) * 2010-12-01 2014-11-26 中国石油化工股份有限公司 丙酰基取代的1,10-菲咯啉配合物的制备及由此制备的配合物作为催化剂的应用
CN106083713B (zh) * 2016-07-15 2019-07-26 浙江工业大学 一种喹(喔)啉-2-甲醛类化合物的化学合成方法
WO2021176428A1 (en) * 2020-03-06 2021-09-10 Jawaharlal Nehru Centre For Advanced Scientific Research Phenanthroline, carbazole and flavylium based cyanines and compositions and methods of making and using the same
CA3232921A1 (en) * 2021-09-28 2023-04-06 Zevra Denmark A/S Oximes and their use in treatment of gba-related diseases
CN117983303B (zh) * 2022-11-01 2026-04-07 万华化学集团股份有限公司 一种金属配合物及其配体,催化剂组合物及香茅醇的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL76345B1 (enExample) * 1971-02-13 1975-06-30

Also Published As

Publication number Publication date
CN101801461A (zh) 2010-08-11
JP2010529167A (ja) 2010-08-26
WO2008152068A2 (en) 2008-12-18
CL2008001719A1 (es) 2009-01-02
MX2009013482A (es) 2010-01-27
US20140011835A1 (en) 2014-01-09
UY31143A1 (es) 2009-01-30
US20100240692A1 (en) 2010-09-23
CA2690455A1 (en) 2008-12-18
AU2008263897A1 (en) 2008-12-18
WO2008152068A3 (en) 2009-05-07
RU2009148821A (ru) 2011-07-20
EP2170464A2 (en) 2010-04-07
EP2002863A1 (en) 2008-12-17
TW200914016A (en) 2009-04-01
US8592446B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20241356A1 (es) Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
EA201290260A1 (ru) Бензимидазол-имидазольные производные
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
MX2012002973A (es) Derivados de pirimidona herbicidas.
CY1115866T1 (el) Τριαζολοπυριμιδινες
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
CY1112997T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟ[1,5-α]ΠΥΡΙΔΙΝΩΝ, Η ΔΙΑΔΙΚΑΣIΑ ΠΑΡΑΣΚΕΥΗΣ ΤΟΥΣ ΚΑΙ ΟΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΑ ΠΕΡΙΕΧΟΥΝ
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
AR063581A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
MX378555B (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
AR055017A1 (es) Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos
PE20091811A1 (es) DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1
CY1116875T1 (el) Διϋδροετορφινες και η παρασκευη αυτων

Legal Events

Date Code Title Description
FB Suspension of granting procedure